TY - JOUR
T1 - Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
AU - Tré-Hardy, Marie
AU - Cupaiolo, Roberto
AU - Wilmet, Alain
AU - Antoine-Moussiaux, Thomas
AU - Della Vecchia, Andrea
AU - Horeanga, Alexandra
AU - Papleux, Emmanuelle
AU - Vekemans, Marc
AU - Beukinga, Ingrid
AU - Blairon, Laurent
N1 - Funding Information:
The authors thank all the members of the clinical laboratory staff for technical assistance. We also thank the HCWs who participated in this study.
Publisher Copyright:
© 2021
PY - 2021/11
Y1 - 2021/11
N2 - Objectives: Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary. Methods: Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire. Results: We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort. Conclusions: In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
AB - Objectives: Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary. Methods: Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire. Results: We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort. Conclusions: In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.
KW - COVID-19
KW - Efficacy
KW - Immunogenicity
KW - mRNA-1273 vaccine
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85114747177&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2021.08.031
DO - 10.1016/j.jinf.2021.08.031
M3 - Article
C2 - 34437927
AN - SCOPUS:85114747177
SN - 0163-4453
VL - 83
SP - 559
EP - 564
JO - Journal of Infection
JF - Journal of Infection
IS - 5
ER -